Funding & Deals
Sep 06, 2026 · 1 min read · 23,432 views
Enveda raises its third megaround in as many years for I&I and weight maintenance drug candidates
L
Liam Turner
Editorial · Sep 06, 2026
Reports indicate that the money continues pouring into Enveda. The Colorado and India startup, which scours the globe's plant and microbe chemistry to create the blueprint for its pipeline, said Wednesday it raised a $311 million
← Previous
Novartis' TREM2 drug fails Phase 2 ALS trial
Next →
BridgeBio Oncology slides as it tightens the scope of its KRAS program
